Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


29.10.2018

1 Aktuelle Urol
1 Asian Pac J Cancer Prev
1 Biosci Rep
1 BMC Cancer
3 BMC Urol
1 Cancer Biol Ther
1 Cancer Manag Res
1 Cell Physiol Biochem
3 Curr Urol Rep
2 Eur Urol
1 Eur Urol Focus
1 Eur Urol Oncol
1 Front Oncol
1 Front Surg
1 In Vivo
1 Int J Cancer
1 Int J Urol
1 J BUON
1 J Cell Biochem
1 J Cell Physiol
1 J Clin Pathol
4 J Urol
1 Medicine (Baltimore)
2 Mol Med Rep
1 Mol Oncol
1 Onco Targets Ther
3 Oncol Lett
1 Oncotarget
1 Open Access Maced J Med Sci
1 Pathol Oncol Res
1 Per Med
1 Res Rep Urol
1 Urol J
6 Urol Oncol
2 Urology
1 Vet Microbiol
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aktuelle Urol

  1. CHEN HR, Kao CC, Tsao CW, Tang SH, et al
    Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients.
    Aktuelle Urol. 2018 Oct 23. doi: 10.1055/a-0750-5595.
    PubMed     Text format     Abstract available


    Asian Pac J Cancer Prev

  2. MISZCZYK M, Majewski W
    Hematologic Toxicity of Conformal Radiotherapy and Intensity Modulated Radiotherapy in Prostate and Bladder Cancer Patients
    Asian Pac J Cancer Prev. 2018;19:2803-2806.
    PubMed     Text format     Abstract available


    Biosci Rep

  3. WANG S, Zhang G, Zheng W, Xue Q, et al
    MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targeting ZEB2.
    Biosci Rep. 2018 Oct 23. pii: BSR20181436. doi: 10.1042/BSR20181436.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. STEFFENSEN EH, Cary C, Jensen JB, Larsson H, et al
    Preadmission antidepressant use and bladder cancer: a population-based cohort study of stage at diagnosis, time to surgery, and surgical outcomes.
    BMC Cancer. 2018;18:1035.
    PubMed     Text format     Abstract available


    BMC Urol

  5. HASHMI AA, Hussain ZF, Irfan M, Khan EY, et al
    Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder.
    BMC Urol. 2018;18:59.
    PubMed     Text format     Abstract available

  6. LENIS AT, Asanad K, Blaibel M, Donin NM, et al
    Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.
    BMC Urol. 2018;18:93.
    PubMed     Text format     Abstract available

  7. GETZLER I, Bahouth Z, Nativ O, Rubinstein J, et al
    Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer.
    BMC Urol. 2018;18:90.
    PubMed     Text format     Abstract available


    Cancer Biol Ther

  8. SUN E, Liu K, Zhao K, Wang L, et al
    Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression.
    Cancer Biol Ther. 2018 Oct 25:1-14. doi: 10.1080/15384047.2018.1529098.
    PubMed     Text format     Abstract available


    Cancer Manag Res

  9. GUO Y, Zhang H, Xie D, Hu X, et al
    Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/beta-catenin pathway.
    Cancer Manag Res. 2018;10:4371-4380.
    PubMed     Text format     Abstract available


    Cell Physiol Biochem

  10. CAO YP, Zhou J, Li WJ, Shao Y, et al
    Long Non-Coding RNA Expression Profiles for the Characterization of Different Bladder Cancer Grade.
    Cell Physiol Biochem. 2018;50:1154-1163.
    PubMed     Text format     Abstract available


    Curr Urol Rep

  11. RISTAU BT, Smaldone MC
    Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care.
    Curr Urol Rep. 2018;19:100.
    PubMed     Text format     Abstract available

  12. NYKOPP TK, Batista da Costa J, Mannas M, Black PC, et al
    Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Curr Urol Rep. 2018;19:101.
    PubMed     Text format     Abstract available

  13. PORTEN SP
    Epigenetic Alterations in Bladder Cancer.
    Curr Urol Rep. 2018;19:102.
    PubMed     Text format     Abstract available


    Eur Urol

  14. GSCHWEND JE, Heck MM, Lehmann J, Rubben H, et al
    Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737.
    PubMed     Text format     Abstract available

  15. GORE JL, Wright JL
    Can We Prevent Bladder Cancer Recurrences?
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30749.
    PubMed     Text format    


    Eur Urol Focus

  16. HOQUE MO
    Differences in the Molecular Characteristics of Bladder Cancer between Smokers and Nonsmokers.
    Eur Urol Focus. 2018;4:98-99.
    PubMed     Text format    


    Eur Urol Oncol

  17. WILLIAMS SB, Kamat AM, Chamie K, Froehner M, et al
    Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.
    Eur Urol Oncol. 2018;1:91-100.
    PubMed     Text format     Abstract available


    Front Oncol

  18. VAN DE MERBEL AF, van der Horst G, van der Mark MH, van Uhm JIM, et al
    An ex vivo Tissue Culture Model for the Assessment of Individualized Drug Responses in Prostate and Bladder Cancer.
    Front Oncol. 2018;8:400.
    PubMed     Text format     Abstract available


    Front Surg

  19. CATTANEO F, Motterle G, Zattoni F, Morlacco A, et al
    The Role of Lymph Node Dissection in the Treatment of Bladder Cancer.
    Front Surg. 2018;5:62.
    PubMed     Text format     Abstract available


    In Vivo

  20. MIKOLAJCZYK A, Khosrawipour V, Schubert J, Plociennik M, et al
    Feasibility and Characteristics of Pressurized Aerosol Chemotherapy (PAC) in the Bladder as a Therapeutical Option in Early-stage Urinary Bladder Cancer.
    In Vivo. 2018;32:1369-1372.
    PubMed     Text format     Abstract available


    Int J Cancer

  21. LEAO R, Lee D, Figueiredo A, Hermanns T, et al
    Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer.
    Int J Cancer. 2018 Oct 23. doi: 10.1002/ijc.31935.
    PubMed     Text format     Abstract available


    Int J Urol

  22. ADELOYE D, Harhay MO, Ayepola OO, Dos Santos JP, et al
    Estimate of the incidence of bladder cancer in Africa: A systematic review and Bayesian meta-analysis.
    Int J Urol. 2018 Oct 21. doi: 10.1111/iju.13824.
    PubMed     Text format     Abstract available


    J BUON

  23. REN D, Yang C, Liu N, Wang Z, et al
    Association between GPX1 and SOD2 genetic polymorphisms and overall survival in patients with metastatic urothelial bladder cancer: a single-center study in Serbia.
    J BUON. 2018;23:1130-1135.
    PubMed     Text format     Abstract available


    J Cell Biochem

  24. HU B, Shi G, Li Q, Li W, et al
    Long noncoding RNA XIST participates in bladder cancer by downregulating p53 via binding to TET1.
    J Cell Biochem. 2018 Oct 25. doi: 10.1002/jcb.27920.
    PubMed     Text format     Abstract available


    J Cell Physiol

  25. SUN M, Zhao W, Chen Z, Li M, et al
    Circ_0058063 regulates CDK6 to promote bladder cancer progression by sponging miR-145-5p.
    J Cell Physiol. 2018 Oct 26. doi: 10.1002/jcp.27280.
    PubMed     Text format     Abstract available


    J Clin Pathol

  26. D ELIA C, Pycha A, Folchini DM, Mian C, et al
    Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
    J Clin Pathol. 2018 Oct 24. pii: jclinpath-2018-205393.
    PubMed     Text format     Abstract available


    J Urol

  27. CHANG SS
    Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.
    J Urol. 2018;200:942-943.
    PubMed     Text format    

  28. GRIEBLING TL
    Re: Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    J Urol. 2018;200:922.
    PubMed     Text format    

  29. PEYTON CC, Henriksen C, Reich RR, Azizi M, et al
    Estimating Minimally Important Differences for the Bladder Cancer Index Using Distribution- and Anchor-Based Approaches.
    J Urol. 2018 Oct 17. pii: S0022-5347(18)43986-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  30. ATALA A
    Re: An FGFR3/MYC Positive Feedback Loop Provides New Opportunities for Targeted Therapies in Bladder Cancers.
    J Urol. 2018;200:947-948.
    PubMed     Text format    


    Medicine (Baltimore)

  31. NAYA Y, Mikami K, Takaha N, Inoue Y, et al
    Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instill
    Medicine (Baltimore). 2018;97:e12740.
    PubMed     Text format     Abstract available


    Mol Med Rep

  32. MAO G, Yao Y, Kong Z
    Long term exposure to gammarays induces radioresistance and enhances the migration ability of bladder cancer cells.
    Mol Med Rep. 2018 Oct 26. doi: 10.3892/mmr.2018.9605.
    PubMed     Text format     Abstract available

  33. LIU A, Zhang Z, Xu W, Qin S, et al
    Overexpression of long noncoding RNA n346372 in bladder cancer tissues is associated with a poor prognosis.
    Mol Med Rep. 2018 Oct 25. doi: 10.3892/mmr.2018.9597.
    PubMed     Text format     Abstract available


    Mol Oncol

  34. IBARRA C, Karlsson M, Codeluppi S, Varas-Godoy M, et al
    BCG-induced cytokine release in bladder cancer cells is regulated by Ca(2+) signaling.
    Mol Oncol. 2018 Oct 25. doi: 10.1002/1878-0261.12397.
    PubMed     Text format     Abstract available


    Onco Targets Ther

  35. ZHAO AY, Dai YJ, Lian JF, Huang Y, et al
    YAP regulates ALDH1A1 expression and stem cell property of bladder cancer cells.
    Onco Targets Ther. 2018;11:6657-6663.
    PubMed     Text format     Abstract available


    Oncol Lett

  36. CAI B, Ma L, Nong S, Wu Y, et al
    beta-elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation.
    Oncol Lett. 2018;16:6019-6025.
    PubMed     Text format     Abstract available

  37. WANG S, Wu G, Han Y, Song P, et al
    miR-124 regulates STAT3-mediated cell proliferation, migration and apoptosis in bladder cancer.
    Oncol Lett. 2018;16:5875-5881.
    PubMed     Text format     Abstract available

  38. KATO Y, Zembutsu H, Takata R, Matsuura T, et al
    A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer.
    Oncol Lett. 2018;16:5775-5784.
    PubMed     Text format     Abstract available


    Oncotarget

  39. HASHIZUME A, Umemoto S, Yokose T, Nakamura Y, et al
    Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.
    Oncotarget. 2018;9:34066-34078.
    PubMed     Text format     Abstract available


    Open Access Maced J Med Sci

  40. WAYAN Y, Ayu PD, Gde OAA, Wayan N, et al
    Pathological Profile, Early Complications, Functional and Oncological Outcome after Radical Cystectomy - Ileal Conduit for Bladder Cancer Patients in Sanglah General Hospital between January 2013 and December 2016.
    Open Access Maced J Med Sci. 2018;6:1647-1651.
    PubMed     Text format     Abstract available


    Pathol Oncol Res

  41. NEDJADI T, Salem N, Khayyat D, Al-Sayyad A, et al
    Sonic Hedgehog Expression is Associated with Lymph Node Invasion in Urothelial Bladder Cancer.
    Pathol Oncol Res. 2018 Oct 25. pii: 10.1007/s12253-018-0477.
    PubMed     Text format     Abstract available


    Per Med

  42. YAZARLOU F, Kholghi-Oskooei V, Afsharpad M, Nekoohesh L, et al
    Expression analysis of a panel of cancer-testis antigens in bladder cancer.
    Per Med. 2018 Oct 26. doi: 10.2217/pme-2018-0049.
    PubMed     Text format     Abstract available


    Res Rep Urol

  43. ZARE R, Grabe M, Hermann GG, Malmstrom PU, et al
    Can routine outpatient follow-up of patients with bladder cancer be improved? A multicenter prospective observational assessment of blue light flexible cystoscopy and fulguration.
    Res Rep Urol. 2018;10:151-157.
    PubMed     Text format     Abstract available


    Urol J

  44. HAMIDI N, Suer E, Ozkidik M, Gokce MI, et al
    Effect of Treatment Modality on Long Term Renal Functions in Patients With Muscle Invasive Bladder Cancer.
    Urol J. 2018 Oct 21. pii: 4251/1310.
    PubMed     Text format     Abstract available


    Urol Oncol

  45. ROYCE TJ, Lin CC, Gray PJ, Shipley WU, et al
    Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base.
    Urol Oncol. 2018;36:78.
    PubMed     Text format     Abstract available

  46. HANNA N, Leow JJ, Sun M, Friedlander DF, et al
    Comparative effectiveness of robot-assisted vs. open radical cystectomy.
    Urol Oncol. 2018;36:88.
    PubMed     Text format     Abstract available

  47. SADOWSKI DJ, Warner H, Scaife S, McVary KT, et al
    30-day all-cause hospital readmission after cystectomy: no worse for rural Medicare residents.
    Urol Oncol. 2018;36:89.
    PubMed     Text format     Abstract available

  48. FAHMY O, Khairul-Asri MG, Schubert T, Renninger M, et al
    Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis.
    Urol Oncol. 2018;36:54-59.
    PubMed     Text format     Abstract available

  49. VON LANDENBERG N, Speed JM, Cole AP, Seisen T, et al
    Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
    Urol Oncol. 2018;36:78.
    PubMed     Text format     Abstract available

  50. OO HZ, Seiler R, Black PC, Daugaard M, et al
    Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.
    Urol Oncol. 2018 Oct 17. pii: S1078-1439(18)30339.
    PubMed     Text format     Abstract available


    Urology

  51. ABBOUD MA, Topham AK, Parker DC, Burks HR, et al
    Risk of Ovarian Malignancy in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    Urology. 2018 Oct 22. pii: S0090-4295(18)31103.
    PubMed     Text format     Abstract available

  52. CHECK DK, Aaronson DS, Nielsen ME, Lee VS, et al
    Perioperative Intravesical Chemotherapy for Patients with Non-Muscle Invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-Recommended Use.
    Urology. 2018 Oct 22. pii: S0090-4295(18)31102.
    PubMed     Text format     Abstract available


    Vet Microbiol

  53. ROPERTO S, Russo V, Rosati A, Ceccarelli DM, et al
    Chaperone-assisted selective autophagy in healthy and papillomavirus-associated neoplastic urothelium of cattle.
    Vet Microbiol. 2018;221:134-142.
    PubMed     Text format     Abstract available


    World J Urol

  54. DAL MORO F
    A specific scoring system able to predict the efficacy of the therapy for bladder cancer: why not?
    World J Urol. 2018 Oct 23. pii: 10.1007/s00345-018-2533.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: